Skip to content

The Impact of Continuous Methylene Blue Infusion on Vascular Tone in Refractory Septic Shock: A Prospective, Observational Study

The Impact of Continuous Methylene Blue Infusion on Vascular Tone in Refractory Septic Shock: A Prospective, Observational Study

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600123806
Enrollment
Unknown
Registered
2026-04-30
Start date
2026-04-30
Completion date
Unknown
Last updated
2026-05-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis with septic shock

Interventions

Methylene Blue Group:None

Sponsors

The First Affiliated Hospital,Sun Yat-sen University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Age > 18 years; 2.Diagnosis of septic shock as defined by the Sepsis-3 criteria (suspected or confirmed infection, requiring norepinephrine to maintain MAP >= 65 mmHg or serum lactate > 2 mmol/L after adequate fluid resuscitation); 3.Receiving intravenous methylene blue infusion with a norepinephrine dose >= 0.25 µg/(kg·min) at the time of administration;

Exclusion criteria

Exclusion criteria: 1.Pregnancy or lactation; 2.Personal or family history of glucose-6-phosphate dehydrogenase (G-6-PD) deficiency; 3.Known allergy to methylene blue; 4.Participation in another interventional clinical trial; 5.Any other condition deemed by the investigator to be inappropriate for participation in this study;

Design outcomes

Primary

MeasureTime frame
Diastolic Shock Index, DSI;

Secondary

MeasureTime frame
28-day vasopressor-free days;28-day all-cause mortality;

Countries

China

Contacts

Public ContactSong Wenliang

The First Affiliated Hospital,Sun Yat-sen University

18907195976@163.com+86 10 12345678

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: May 7, 2026